At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 54 enrolled
Drug / intervention
Lipotecandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) When Administered to Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Lipotecan for Advanced Solid Tumors. Completed, enrolled 54 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this study is to find a safe and tolerable dose of Lipotecan® when administered to patients with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesTaiwan, United States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Primary CompletionAug 2011
Study CompletionDec 2011
TodayJul 2026
First PostedSep 5, 2008
Enrollment StartSep 1, 2008
Primary CompletionAug 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.8 years ago
Interventions
Lipotecandrug
Lipotecan IV day 1, 8, 15